Rigel Appoints Michael P. Miller to the Board of Directors

Rhea-AI Summary

Rigel (Nasdaq: RIGL) appointed Michael P. Miller to its Board of Directors effective Feb. 3, 2026. Mr. Miller brings over four decades of commercial and leadership experience across biotechnology and pharmaceuticals, including executive commercial roles at Jazz Pharmaceuticals and Genentech and current board service at Puma Biotechnology and BioXcel Therapeutics.

The company said his commercial expertise will support Rigel's strategic plan to grow marketed medicines and evaluate in-licensing opportunities to expand its hematologic and oncology portfolio.

Positive

• Appointed Michael P. Miller to the Board on Feb 3, 2026
• Mr. Miller has 40+ years of commercial biopharma experience
• Serves on boards of Puma Biotechnology and BioXcel Therapeutics
• Former Executive VP of U.S. Commercial at Jazz Pharmaceuticals (2014–2020)

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries.

"Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board," said Raul Rodriguez, Rigel's president and CEO. "His extensive expertise in commercial execution and leadership will provide valuable insights as we execute on our transformational strategic plan, particularly our objectives of growing our current portfolio of medicines and evaluating potential in-licensing opportunities – areas where Mike has extensive experience."

Mr. Miller currently serves on the Board of Directors at Puma Biotechnology and BioXcel Therapeutics. He served as the Executive Vice President of U.S. Commercial of Jazz Pharmaceuticals from April 2014 until his retirement in September 2020. Before that, Mr. Miller was Senior Vice President and Chief Commercial Officer of Vivus. Prior to that, Mr. Miller served as Vice President, leading the HER Family Oncology franchise, of Genentech. Other roles included Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories (GSK); Vice President of the of ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson; and various sales and marketing positions at Syntex Corporation. Mr. Miller earned a B.S. in Business Administration and Finance from the University of San Francisco and an M.B.A. in Information and Computer Systems from San Francisco State University.

"Over the years I have seen Rigel evolve into a profitable company with a strong commercial engine that can fund a promising development pipeline, which is a privileged position in biotechnology space," said Mr. Miller. "I am thrilled to join Rigel as a Director and contribute to the critical work focused on realizing opportunities to serve more patients with hematologic disorders and cancer."

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com 

Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-appoints-michael-p-miller-to-the-board-of-directors-302677011.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

Who is Michael P. Miller and why did Rigel (RIGL) appoint him to the board on Feb 3, 2026?

He is a commercial biopharma executive with over four decades of experience. According to the company, his track record in commercial execution and leadership will help Rigel grow marketed medicines and assess in-licensing opportunities to expand its hematology and oncology offerings.

What roles has Michael P. Miller held before joining Rigel's board (RIGL)?

He held senior commercial positions across biopharma, including Executive VP of U.S. Commercial at Jazz Pharmaceuticals. According to the company, prior roles include Chief Commercial Officer at Vivus and commercial leadership at Genentech, ALZA, Connetics, and Syntex.

How might Michael Miller's appointment affect Rigel's strategy and pipeline (RIGL)?

His appointment is intended to strengthen commercial execution and portfolio growth. According to the company, Miller's experience is expected to support efforts to grow current medicines and evaluate in-licensing to broaden Rigel's hematologic and oncology pipeline.

Does Michael Miller currently serve on other corporate boards prior to joining Rigel (RIGL)?

Yes. He currently serves on the boards of Puma Biotechnology and BioXcel Therapeutics. According to the company, his active board roles add governance and commercial perspective relevant to Rigel's strategic objectives.

When was Michael Miller Executive VP of U.S. Commercial at Jazz Pharmaceuticals and how is that relevant to Rigel (RIGL)?

He served as Executive VP of U.S. Commercial from April 2014 until retirement in September 2020. According to the company, that tenure demonstrates senior commercial leadership experience applicable to scaling Rigel's marketed products and commercial strategy.